Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial
Authors not listed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1997
Abstract
The purpose of this study is to evaluate the safety and effectiveness of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease using a flexible dose design.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (1997). Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial. <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00253227
Vancouver
Anonymous. Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 1997.
BibTeX
@misc{anon1997Galant,
title = {Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial},
author = {Anonymous},
journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.},
year = {1997},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2001
Open access · US-GOV
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2000
Open access · US-GOV
Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2004
Open access · US-GOV
Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease
University of Washington 2005
Open access · US-GOV
Behavioral Treatment of Nocturnal Disturbances in Alzheimer's Disease
JHSPH Center for Clinical Trials 2009
Open access · US-GOV
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease
Florida Atlantic University 2007
Open access · US-GOV